厚生劳动省专家小组有条件批准了两款用于治疗帕金森病和严重心脏病的诱导多能干（iPS）细胞衍生再生医学产品。这标志着诺贝尔奖获奖干细胞技术商业化的潜在世界首例。该批准基于小规模临床试验确认的安全性和假定疗效，要求在七年内在上市后进行验证。
2026年2月20日，日本厚生劳动省下属专家小组有条件且限期批准了两款诱导多能干（iPS）细胞衍生再生医学产品的制造和销售。其中包括住友制药与京都大学合作开发的用于帕金森病的神经细胞产品Amchepry，以及大阪大学Cuorips公司开发的用于严重心力衰竭的心肌细胞贴片。
X用户大多庆祝日本有条件批准iPS细胞疗法用于帕金森病和严重心力衰竭，这是再生医学的世界首创里程碑，归功于诺贝尔奖得主山中伸弥的技术。政客和生物技术领袖对全球患者带来益处表示乐观，普通用户分享兴奋和个人希望故事。少数声音对试验规模小和进程仓促表示怀疑，强调需进行上市后验证。
昨日（2月19日）、厚生労働省の審議会で、iPS細胞を用いた再生医療等製品の世界で初めてとなる薬事承認が、重度の心臓病に使用する「リハート」と、パーキンソン病に使用する「アムシェプリ」の２製品について、条件及び期限付きで可とされました。…
— 高市早苗 (@takaichi_sanae) 20. helmikuuta 2026
🌱お昼〜🍱😄
— 爺ちゃん🧙 (@WINDY_WEEDS) 20. helmikuuta 2026
速報‼️
朗報(^O^)／💥
キタキター🥳
遂に実用化GO💨
🧬🇯🇵✨
iPS細胞
歴史的爆進‼️🚀
❤️🫀心筋シートで
心不全対策🩺💡
🧠⚡パーキンソン病＝神経元細胞移植
症状改善へ🔬💉
🏛️厚労省が承認📜
⏳7年内の本承認
《条件》🙋
機能💪回復🏋️医療🏥
が実現だぁ〜🤩 pic.twitter.com/ijDIrO0wsB
A historic day yesterday!! Feb 19, 2026- Two conditional approvals in Japan - heart failure and Parkinson's! The future of iPSC-derived cellular medicines is... here, and more to come 🧠❤️🩹🥳 pic.twitter.com/3COIpygnyj
— Dr. Nabiha Saklayen (@nabsicle) 20. helmikuuta 2026
重症心不全は8例、パーキンソン病は6例、iPS細胞だとわずか一桁の試験結果でも承認されるとか民間療法も真っ青なダブルスタンダードスピード承認。流石に「世界初」の冠の為だけに色々なプロセスをすっ飛ばし過ぎなんじゃないかな？ https://t.co/xU4iPWE4oA
— なお@視力回復＆飛蚊症改善&緑内障情報収集中 (@me_nao_su) 20. helmikuuta 2026
ｉＰＳ細胞由来製品を承認へ 心疾患とパーキンソン病治療―世界初の実用化 時事ドットコム
— rikorikosawsi 猫と狂気が詰まってる💚推し (@rikorikosawsi) 20. helmikuuta 2026
母は待てなかった
IPS細胞の研究が進んでいると励まし続けたけれど間に合いませんでした
でもこれで多くの人が助かる
パーキンソンに苦しむ方々
もう少しです
頑張って！ https://t.co/jVvQtI1uxB
由 AI 报道 AI 生成的图像 事实核查
Keck Medicine of USC researchers are testing an experimental approach to Parkinson’s disease that implants lab-grown, dopamine-producing cells into a movement-control region of the brain. The early-stage Phase 1 REPLACE trial involves up to 12 people with moderate to moderate-severe Parkinson’s disease, and the U.S. Food and Drug Administration has granted the study fast-track designation.
Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products derived from iPS cells, marking a global first. These treatments target patients with severe heart failure and Parkinson's disease, under a conditional approval requiring data collection for up to seven years. Shinya Yamanaka, pioneer of iPS cell research, expressed delight at this milestone.
由 AI 报道
Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.
Scientists at KAIST in South Korea have developed a novel therapy that transforms a tumor's own immune cells into potent cancer fighters directly inside the body. By injecting lipid nanoparticles into tumors, the treatment reprograms macrophages to produce cancer-recognizing proteins, overcoming barriers in solid tumor treatment. Early animal studies show promising reductions in tumor growth.
由 AI 报道
The US Food and Drug Administration has granted fast-track status to an innovative inhalable gene therapy for advanced lung cancer, following promising early trial results. Developed by Krystal Biotech, the treatment uses a modified virus to deliver immune-boosting genes directly to lung cells via inhalation. In initial tests, it shrank tumors in some patients and halted growth in others.